Skip to content
2000
Volume 33, Issue 4
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Introduction

Regulatory T cells (Tregs) play an important role in the tumor microenvironment (TME). Currently, there have been no studies of Treg-related genes (TRGs) in lung adenocarcinoma (LUAD).

Methods

We integrated the Cancer Genome Atlas (TCGA) dataset with the Gene Expression Omnibus (GEO) dataset and divided the TCGA-GEO dataset patient samples into different cohorts by unsupervised clustering analysis based on the expression of TRGs in LUAD. By analyzing the TME characteristics of different cohorts, we assessed immune cell infiltration and function. In addition, we constructed Cox risk proportional regression models based on TRGs to predict patient prognosis.

Results

The results of unsupervised cluster analysis classified the TCGA-GEO dataset as “immune desert”, “immune evasion” and “immune inflammation”. Moreover, there was a significant survival differential among the three cohorts (-value < 0.05). Based on the expression of 61 TRGs in LUAD, we screened TFRC, CTLA4, IL1R2, NPTN NPTN and METTL7A to construct a Cox risk proportional regression model to divide the TCGA-GEO dataset into a training cohort and a test cohort. Survival was significantly worse in the high-risk group than in the low-risk group in both the training and test cohorts (-value < 0.05). Finally, the nomogram scoring system constructed by integrating the model risk scores with clinical parameters can well predict the 1, 3 and 5 year survival of patients.

Conclusion

In conclusion, based on our analysis of the TRGs of LUAD patients, we can classify the patient TME into different immune statuses, which provides insights into adopting appropriate treatment regimens for different patients.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673375015250513094405
2025-07-10
2026-02-23

  • From This Site

    /content/journals/cmc/10.2174/0109298673375015250513094405
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmc/33/4/CMC-33-4-07.html?itemId=/content/journals/cmc/10.2174/0109298673375015250513094405&mimeType=html&fmt=ahah

References

  1. MolinaJ.R. YangP. CassiviS.D. SchildS.E. AdjeiA.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship.Mayo Clin. Proc.200883558459410.1016/S0025‑6196(11)60735‑018452692
     [Google Scholar]
  2. AberleD.R. AdamsA.M. BergC.D. BlackW.C. ClappJ.D. FagerstromR.M. GareenI.F. GatsonisC. MarcusP.M. SicksJ.D. Reduced lung-cancer mortality with low-dose computed tomographic screening.N. Engl. J. Med.2011365539540910.1056/NEJMoa110287321714641
     [Google Scholar]
  3. MillerM. HannaN. Advances in systemic therapy for non-small cell lung cancer.BMJ2021375n236310.1136/bmj.n236334753715
     [Google Scholar]
  4. ChaftJ.E. ShyrY. SepesiB. FordeP.M. Preoperative and postoperative systemic therapy for operable non–small-cell lung cancer.J. Clin. Oncol.202240654655510.1200/JCO.21.0158934985966
     [Google Scholar]
  5. DumaN. Santana-DavilaR. MolinaJ.R. Non–small cell lung cancer: Epidemiology, screening, diagnosis, and treatment.Mayo Clin. Proc.20199481623164010.1016/j.mayocp.2019.01.01331378236
     [Google Scholar]
  6. ThaiA.A. SolomonB.J. SequistL.V. GainorJ.F. HeistR.S. Lung cancer.Lancet20213981029953555410.1016/S0140‑6736(21)00312‑334273294
     [Google Scholar]
  7. ZhangY. ZhangZ. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cell. Mol. Immunol.202017880782110.1038/s41423‑020‑0488‑632612154
     [Google Scholar]
  8. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  9. SakaguchiS. SakaguchiN. AsanoM. ItohM. TodaM. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J. Immunol.199515531151116410.4049/jimmunol.155.3.11517636184
     [Google Scholar]
  10. SakaguchiS. MikamiN. WingJ.B. TanakaA. IchiyamaK. OhkuraN. Regulatory T cells and human disease.Annu. Rev. Immunol.202038154156610.1146/annurev‑immunol‑042718‑04171732017635
     [Google Scholar]
  11. ZouW. Regulatory T cells, tumour immunity and immunotherapy.Nat. Rev. Immunol.20066429530710.1038/nri180616557261
     [Google Scholar]
  12. TogashiY. ShitaraK. NishikawaH. Regulatory T cells in cancer immunosuppression - Implications for anticancer therapy.Nat. Rev. Clin. Oncol.201916635637110.1038/s41571‑019‑0175‑730705439
     [Google Scholar]
  13. TayC. TanakaA. SakaguchiS. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.Cancer Cell202341345046510.1016/j.ccell.2023.02.01436917950
     [Google Scholar]
  14. GanM. LiuN. LiW. ChenM. BaiZ. LiuD. LiuS. Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: New horizons in immunotherapy.Mol. Cancer202423127310.1186/s12943‑024‑02193‑739696340
     [Google Scholar]
  15. BuechlerM.B. FuW. TurleyS.J. Fibroblast- macrophage reciprocal interactions in health, fibrosis, and cancer.Immunity202154590391510.1016/j.immuni.2021.04.02133979587
     [Google Scholar]
  16. HeS. ZhengL. QiC. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.Mol. Cancer2025241510.1186/s12943‑024‑02208‑339780248
     [Google Scholar]
  17. LiC. JiangP. WeiS. XuX. WangJ. Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects.Mol. Cancer202019111610.1186/s12943‑020‑01234‑132680511
     [Google Scholar]
  18. GhoraniE. SwantonC. QuezadaS.A. Cancer cell-intrinsic mechanisms driving acquired immune tolerance.Immunity202356102270229510.1016/j.immuni.2023.09.00437820584
     [Google Scholar]
  19. BeyerM. SchultzeJ.L. Regulatory T cells in cancer.Blood2006108380481110.1182/blood‑2006‑02‑00277416861339
     [Google Scholar]
  20. HegdeP.S. KaranikasV. EversS. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition.Clin. Cancer Res.20162281865187410.1158/1078‑0432.CCR‑15‑150727084740
     [Google Scholar]
  21. FanY. ZhouY. LouM. LiX. ZhuX. YuanK. m6A regulator-mediated methylation modification patterns and characterisation of tumour microenvironment infiltration in non-small cell lung cancer.J. Inflamm. Res.2022151969198910.2147/JIR.S35684135356071
     [Google Scholar]
  22. ChongW. ShangL. LiuJ. FangZ. DuF. WuH. LiuY. WangZ. ChenY. JiaS. ChenL. LiL. ChenH. m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer.Theranostics20211152201221710.7150/thno.5271733500720
     [Google Scholar]
  23. HuppertL.A. GreenM.D. KimL. ChowC. LeyfmanY. DaudA.I. LeeJ.C. Tissue-specific tregs in cancer metastasis: Opportunities for precision immunotherapy.Cell. Mol. Immunol.2022191334510.1038/s41423‑021‑00742‑434417572
     [Google Scholar]
  24. YuJ. XieM. GeS. ChaiP. ZhouY. RuanJ. Hierarchical clustering of Cutaneous melanoma based on immunogenomic profiling.Front. Oncol.20201058002910.3389/fonc.2020.58002933330057
     [Google Scholar]
  25. HeY. JiangZ. ChenC. WangX. Classification of triple-negative breast cancers based on immunogenomic profiling.J. Exp. Clin. Cancer Res.201837132710.1186/s13046‑018‑1002‑130594216
     [Google Scholar]
  26. ZhangY. LiuN. WangS. A differential privacy protecting K-means clustering algorithm based on contour coefficients.PLoS One20181311e020683210.1371/journal.pone.020683230462662
     [Google Scholar]
  27. HänzelmannS. CasteloR. GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-Seq data.BMC Bioinformatics2013141710.1186/1471‑2105‑14‑723323831
     [Google Scholar]
  28. HuJ. ZhangL. XiaH. YanY. ZhuX. SunF. SunL. LiS. LiD. WangJ. HanY. ZhangJ. BianD. YuH. ChenY. FanP. MaQ. JiangG. WangC. ZhangP. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.Genome Med.20231511410.1186/s13073‑023‑01164‑936869384
     [Google Scholar]
  29. IasonosA. SchragD. RajG.V. PanageasK.S. How to build and interpret a nomogram for cancer prognosis.J. Clin. Oncol.20082681364137010.1200/JCO.2007.12.979118323559
     [Google Scholar]
  30. LiJ.H. LiuS. ZhouH. QuL.H. YangJ.H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data.Nucleic Acids Res.201442D1D92D9710.1093/nar/gkt124824297251
     [Google Scholar]
  31. MeyerM.L. FitzgeraldB.G. Paz-AresL. CappuzzoF. JänneP.A. PetersS. HirschF.R. New promises and challenges in the treatment of advanced non-small-cell lung cancer.Lancet20244041045480382210.1016/S0140‑6736(24)01029‑839121882
     [Google Scholar]
  32. MeyerM.L. PetersS. MokT.S. LamS. YangP.C. AggarwalC. BrahmerJ. DziadziuszkoR. FelipE. FerrisA. FordeP.M. GrayJ. GrosL. HalmosB. HerbstR. JänneP.A. JohnsonB.E. KellyK. LeighlN.B. LiuS. LowyI. MarronT.U. Paz-AresL. RizviN. RudinC.M. ShumE. StahelR. TrunovaN. BunnP.A. HirschF.R. Lung cancer research and treatment: Global perspectives and strategic calls to action.Ann. Oncol.202435121088110410.1016/j.annonc.2024.10.00639413875
     [Google Scholar]
  33. ReckM. RemonJ. HellmannM.D. First-line immunotherapy for non–small-cell lung cancer.J. Clin. Oncol.202240658659710.1200/JCO.21.0149734985920
     [Google Scholar]
  34. DoroshowD.B. SanmamedM.F. HastingsK. PolitiK. RimmD.L. ChenL. MeleroI. SchalperK.A. HerbstR.S. Immunotherapy in non–small cell lung cancer: Facts and hopes.Clin. Cancer Res.201925154592460210.1158/1078‑0432.CCR‑18‑153830824587
     [Google Scholar]
  35. HendriksL.E.L. RemonJ. Faivre-FinnC. GarassinoM.C. HeymachJ.V. KerrK.M. TanD.S.W. VeronesiG. ReckM. Non-small-cell lung cancer.Nat. Rev. Dis. Primers20241017110.1038/s41572‑024‑00551‑939327441
     [Google Scholar]
  36. WangY. SafiM. HirschF.R. LuS. PetersS. GovindanR. RosellR. ParkK. ZhangJ.J. Immunotherapy for advanced-stage squamous cell lung cancer: The state of the art and outstanding questions.Nat. Rev. Clin. Oncol.202522320021410.1038/s41571‑024‑00979‑839762577
     [Google Scholar]
  37. LainéA. LabiadO. Hernandez-VargasH. ThisS. SanlavilleA. LéonS. DalleS. SheppardD. TravisM.A. PaidassiH. MarieJ.C. Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation.Nat. Commun.2021121622810.1038/s41467‑021‑26352‑234711823
     [Google Scholar]
  38. HuangH. WangZ. ZhangY. PradhanR.N. GangulyD. ChandraR. MurimwaG. WrightS. GuX. MaddipatiR. MüllerS. TurleyS.J. BrekkenR.A. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer.Cancer Cell2022406656673.e710.1016/j.ccell.2022.04.01135523176
     [Google Scholar]
  39. WuS.P. LiaoR.Q. TuH.Y. WangW.J. DongZ.Y. HuangS.M. GuoW.B. GouL.Y. SunH.W. ZhangQ. XieZ. YanL.X. SuJ. YangJ.J. ZhongW.Z. ZhangX.C. WuY.L. Stromal PD-L1–positive regulatory T cells and PD-1–positive CD8-positive T cells define the response of different subsets of non–small cell lung cancer to PD-1/PD-L1 blockade immunotherapy.J. Thorac. Oncol.201813452153210.1016/j.jtho.2017.11.13229269008
     [Google Scholar]
  40. ZhangA. FanT. LiuY. YuG. LiC. JiangZ. Regulatory T cells in immune checkpoint blockade antitumor therapy.Mol. Cancer202423125110.1186/s12943‑024‑02156‑y39516941
     [Google Scholar]
  41. YanY. HuangL. LiuY. YiM. ChuQ. JiaoD. WuK. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: Implications for antitumor immunity.J. Hematol. Oncol.202215110410.1186/s13045‑022‑01322‑335948909
     [Google Scholar]
  42. HegdeP.S. ChenD.S. Top 10 challenges in cancer immunotherapy.Immunity2020521173510.1016/j.immuni.2019.12.01131940268
     [Google Scholar]
  43. PetroniG. BuquéA. ZitvogelL. KroemerG. GalluzziL. Immunomodulation by targeted anticancer agents.Cancer Cell202139331034510.1016/j.ccell.2020.11.00933338426
     [Google Scholar]
  44. DingQ.Q. ChauvinJ.M. ZarourH.M. Targeting novel inhibitory receptors in cancer immunotherapy.Semin. Immunol.20204910143610.1016/j.smim.2020.10143633288379
     [Google Scholar]
  45. SolomonI. AmannM. GoubierA. Arce VargasF. ZervasD. QingC. HenryJ.Y. GhoraniE. AkarcaA.U. MarafiotiT. ŚledzińskaA. Werner SunderlandM. Franz DemaneD. ClancyJ.R. GeorgiouA. SalimuJ. MerchiersP. BrownM.A. FluryR. EckmannJ. MurgiaC. SamJ. JacobsenB. Marrer-BergerE. BoetschC. BelliS. LeibrockL. BenzJ. KollH. SutmullerR. PeggsK.S. QuezadaS.A. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.Nat. Cancer20201121153116610.1038/s43018‑020‑00133‑033644766
     [Google Scholar]
  46. DovediS.J. ElderM.J. YangC. SitnikovaS.I. IrvingL. HansenA. HairJ. JonesD.C. HasaniS. WangB. ImS.A. TranB. SubramaniamD.S. GainerS.D. VashishtK. LewisA. JinX. KentnerS. MulgrewK. WangY. OverstreetM.G. DodgsonJ. WuY. PalazonA. MorrowM. RaineyG.J. BrowneG.J. NealF. MurrayT.V. ToloczkoA.D. Dall’AcquaW. AchourI. FreemanD.J. WilkinsonR.W. MazorY. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1+ activated T cells.Cancer Discov.20211151100111710.1158/2159‑8290.CD‑20‑144533419761
     [Google Scholar]
  47. ChenD.S. MellmanI. Elements of cancer immunity and the cancer–immune set point.Nature2017541763732133010.1038/nature2134928102259
     [Google Scholar]
  48. LiuY. XunZ. MaK. LiangS. LiX. ZhouS. SunL. LiuY. DuY. GuoX. CuiT. ZhouH. WangJ. YinD. SongR. ZhangS. CaiW. MengF. GuoH. ZhangB. YangD. BaoR. HuQ. WangJ. YeY. LiuL. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.J. Hepatol.202378477078210.1016/j.jhep.2023.01.01136708811
     [Google Scholar]
  49. LeiX. LeiY. LiJ.K. DuW.X. LiR.G. YangJ. LiJ. LiF. TanH.B. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.Cancer Lett.202047012613310.1016/j.canlet.2019.11.00931730903
     [Google Scholar]
  50. OsipovA. SaungM.T. ZhengL. MurphyA.G. Small molecule immunomodulation: The tumor microenvironment and overcoming immune escape.J. Immunother. Cancer20197122410.1186/s40425‑019‑0667‑031439034
     [Google Scholar]
  51. O’DonnellJ.S. TengM.W.L. SmythM.J. Cancer immunoediting and resistance to T cell-based immunotherapy.Nat. Rev. Clin. Oncol.201916315116710.1038/s41571‑018‑0142‑830523282
     [Google Scholar]
  52. YiL. PanH. NingZ. XuL. ZhangH. PengL. LiuY. YangY. SiW. WangY. ZhuX. HuangS. MengZ. XieJ. Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: A phase II trial.Signal Transduct. Target. Ther.20249134710.1038/s41392‑024‑02052‑339668159
     [Google Scholar]
  53. YiM. LiT. NiuM. ZhangH. WuY. WuK. DaiZ. Targeting cytokine and chemokine signaling pathways for cancer therapy.Signal Transduct. Target. Ther.20249117610.1038/s41392‑024‑01868‑339034318
     [Google Scholar]
  54. ChoiS.H. MyersJ.T. TomchuckS.L. BonnerM. EidS. KingsleyD.T. VanHeystK.A. KimS.J. KimB.G. HuangA.Y.C. Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity.Cancer Commun.202444888488810.1002/cac2.1258938970391
     [Google Scholar]
  55. WangH. WangT. YanS. TangJ. ZhangY. WangL. XuH. TuC. Crosstalk of pyroptosis and cytokine in the tumor microenvironment: From mechanisms to clinical implication.Mol. Cancer202423126810.1186/s12943‑024‑02183‑939614288
     [Google Scholar]
  56. Iglesias-EscuderoM. Arias-GonzálezN. Martínez-CáceresE. Regulatory cells and the effect of cancer immunotherapy.Mol. Cancer20232212610.1186/s12943‑023‑01714‑036739406
     [Google Scholar]
  57. KoyamaS. NishikawaH. Mechanisms of regulatory T cell infiltration in tumors: Implications for innovative immune precision therapies.J. Immunother. Cancer202197e00259110.1136/jitc‑2021‑00259134330764
     [Google Scholar]
  58. FujiS. InoueY. UtsunomiyaA. MoriuchiY. UchimaruK. ChoiI. OtsukaE. HenzanH. KatoK. TomoyoseT. YamamotoH. KurosawaS. MatsuokaK. YamaguchiT. FukudaT. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality.J. Clin. Oncol.201634283426343310.1200/JCO.2016.67.825027507878
     [Google Scholar]
  59. DoiT. MuroK. IshiiH. KatoT. TsushimaT. TakenoyamaM. OizumiS. GemmotoK. SunaH. EnokitaniK. KawakamiT. NishikawaH. YamamotoN. A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors.Clin. Cancer Res.201925226614662210.1158/1078‑0432.CCR‑19‑109031455681
     [Google Scholar]
  60. DanielssonJ. MuX. LangL. WangH. BinolfiA. TheilletF.X. BekeiB. LoganD.T. SelenkoP. WennerströmH. OlivebergM. Thermodynamics of protein destabilization in live cells.Proc. Natl. Acad. Sci. USA201511240124021240710.1073/pnas.151130811226392565
     [Google Scholar]
  61. WongT.S. RajagopalanS. TownsleyF.M. FreundS.M. PetrovichM. LoakesD. FershtA.R. Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53.Nucleic Acids Res.200837256858110.1093/nar/gkn97419066201
     [Google Scholar]
  62. HymanA.A. WeberC.A. JülicherF. Liquid-liquid phase separation in biology.Annu. Rev. Cell Dev. Biol.2014301395810.1146/annurev‑cellbio‑100913‑01332525288112
     [Google Scholar]
  63. AguzziA. AltmeyerM. Phase separation: Linking cellular compartmentalization to disease.Trends Cell Biol.201626754755810.1016/j.tcb.2016.03.00427051975
     [Google Scholar]
  64. BasanM. RislerT. JoannyJ.F. Sastre-GarauX. ProstJ. Homeostatic competition drives tumor growth and metastasis nucleation.HFSP J.20093426527210.2976/1.308673220119483
     [Google Scholar]
  65. JoyceJ.A. FearonD.T. T cell exclusion, immune privilege, and the tumor microenvironment.Science20153486230748010.1126/science.aaa620425838376
     [Google Scholar]
  66. TanakaA. SakaguchiS. Regulatory T cells in cancer immunotherapy.Cell Res.201727110911810.1038/cr.2016.15127995907
     [Google Scholar]
  67. JunttilaM.R. de SauvageF.J. Influence of tumour micro-environment heterogeneity on therapeutic response.Nature2013501746734635410.1038/nature1262624048067
     [Google Scholar]
  68. BinnewiesM. RobertsE.W. KerstenK. ChanV. FearonD.F. MeradM. CoussensL.M. GabrilovichD.I. Ostrand-RosenbergS. HedrickC.C. VonderheideR.H. PittetM.J. JainR.K. ZouW. HowcroftT.K. WoodhouseE.C. WeinbergR.A. KrummelM.F. Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat. Med.201824554155010.1038/s41591‑018‑0014‑x29686425
     [Google Scholar]
  69. TangR. WangH. LiuJ. SongL. HouH. LiuM. WangJ. WangJ. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.Eur. J. Med. Res.202429111210.1186/s40001‑024‑01688‑938336764
     [Google Scholar]
  70. WangD.R. WuX.L. SunY.L. Therapeutic targets and biomarkers of tumor immunotherapy: Response versus non-response.Signal Transduct. Target. Ther.20227133110.1038/s41392‑022‑01136‑236123348
     [Google Scholar]
  71. LaletinV. BernardP.L. Costa da SilvaC. GuittardG. NunesJ.A. Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets.J. Immunother. Cancer2023115e00584510.1136/jitc‑2022‑00584537217244
     [Google Scholar]
  72. SkoulidisF. AraujoH.A. DoM.T. QianY. SunX. CoboA.G. LeJ.T. MontesionM. PalmerR. JahchanN. JuanJ.M. MinC. YuY. PanX. ArbourK.C. VokesN. SchmidtS.T. MolkentineD. OwenD.H. MemmottR. PatilP.D. MarmarelisM.E. AwadM.M. MurrayJ.C. HellyerJ.A. GainorJ.F. DimouA. BestvinaC.M. ShuC.A. RiessJ.W. BlakelyC.M. PecotC.V. MezquitaL. TabbóF. SchefflerM. DigumarthyS. MooradianM.J. SacherA.G. LauS.C.M. SaltosA.N. RotowJ. JohnsonR.P. LiuC. StewartT. GoldbergS.B. KillamJ. WaltherZ. SchalperK. DaviesK.D. WoodcockM.G. AnagnostouV. MarroneK.A. FordeP.M. RicciutiB. VenkatramanD. Van AllenE.M. CummingsA.L. GoldmanJ.W. ShaishH. KierM. KatzS. AggarwalC. NiY. AzokJ.T. SegalJ. RitterhouseL. NealJ.W. LacroixL. ElaminY.Y. NegraoM.V. LeX. LamV.K. LewisW.E. KempH.N. CarterB. RothJ.A. SwisherS. LeeR. ZhouT. PoteeteA. KongY. TakeharaT. PaulaA.G. Parra CuentasE.R. BehrensC. WistubaI.I. ZhangJ. BlumenscheinG.R. GayC. ByersL.A. GibbonsD.L. TsaoA. LeeJ.J. BivonaT.G. CamidgeD.R. GrayJ.E. LeighlN.B. LevyB. BrahmerJ.R. GarassinoM.C. GandaraD.R. GaronE.B. RizviN.A. ScagliottiG.V. WolfJ. PlanchardD. BesseB. HerbstR.S. WakeleeH.A. PennellN.A. ShawA.T. JänneP.A. CarboneD.P. HellmannM.D. RudinC.M. AlbackerL. MannH. ZhuZ. LaiZ. StewartR. PetersS. JohnsonM.L. WongK.K. HuangA. WinslowM.M. RosenM.J. WintersI.P. PapadimitrakopoulouV.A. CasconeT. JewsburyP. HeymachJ.V. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Nature2024635803846247110.1038/s41586‑024‑07943‑739385035
     [Google Scholar]
  73. SunQ. HongZ. ZhangC. WangL. HanZ. MaD. Immune checkpoint therapy for solid tumours: Clinical dilemmas and future trends.Signal Transduct. Target. Ther.20238132010.1038/s41392‑023‑01522‑437635168
     [Google Scholar]
  74. ZhangY. MaD. GongY. WangF. WuJ. WuC. IL1R2 is a novel prognostic biomarker for lung adenocarcinoma.Curr. Mol. Med.202424562062910.2174/156652402366623042009214237078353
     [Google Scholar]
  75. KettunenE. Hernandez-VargasH. CrosM.P. DurandG. Le Calvez-KelmF. StuopelyteK. JarmalaiteS. SalmenkiviK. AnttilaS. WolffH. HercegZ. Husgafvel-PursiainenK. Asbestos-associated genome-wide DNA methylation changes in lung cancer.Int. J. Cancer2017141102014202910.1002/ijc.3089728722770
     [Google Scholar]
  76. Rodriguez-PintoD. SparkowskiJ. KeoughM.P. PhoenixK.N. VumbacaF. HanD.K. GundelfingerE.D. BeesleyP. ClaffeyK.P. Identification of novel tumor antigens with patient-derived immune-selected antibodies.Cancer Immunol. Immunother.200958222123410.1007/s00262‑008‑0543‑018568347
     [Google Scholar]
  77. LiuZ. ChenY. ShenT. Evidence based on an integrative analysis of multi-omics data on METTL7A as a molecular marker in pan-cancer.Biomolecules202313219510.3390/biom1302019536830565
     [Google Scholar]
  78. PanY.Q. XiaoY. LiZ. TaoL. ChenG. ZhuJ.F. LvL. LiuJ.C. QiJ.Q. ShaoA. Comprehensive analysis of the significance of METTL7A gene in the prognosis of lung adenocarcinoma.Front. Oncol.202212107110010.3389/fonc.2022.107110036620541
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673375015250513094405
Loading
Characterization of Tumor Microenvironment and Prognosis of Regulatory T cells-Related Subtypes
Curr. Med. Chem. 33, 816 (2026); https://doi.org/10.2174/0109298673375015250513094405
/content/journals/cmc/10.2174/0109298673375015250513094405
/content/journals/cmc/10.2174/0109298673375015250513094405
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): immune infiltration; immunosuppressive cells; precision oncology; prognostic model; survival analysis; Tumor microenvironment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test